Ocular Side-Effects Associated with Imatinib Mesylate (Gleevec ® )
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70%) of the patients at OHSU developed periorbital edema and 19 patients (18%) developed epiphora after receiving imatinib mesylate. Average dose was 407.5+/-60 mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citation
Cited by
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Tamura, A., Onishi, Y., An, R., Koshiba, S., Wakabayashi, K., Hoshijima, K., Priebe, W., Yoshida, T., Kometani, S., Matsubara, T., et al. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.428 · Cited by 72
Tamura, A., An, R., Hagiya, Y., Hoshijima, K., Yoshida, T., Mikuriya, K., & Ishikawa, T. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.3.255 · Cited by 16
Metadata
- Authors
- Fraunfelder, F. W., Solomon, J., Druker, B. J., Esmaeli, B., & Kuyl, J.
- Venue
- Journal of Ocular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 2003-08
- Volume
- 19
- Issue
- 4
- Pages
- 371-375
- ISSN
- 1080-7683 (ISSN-L)
- 1557-7732
- OpenAlex
- W2061874656
- Cited by
- 123
- References
- 2
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ocular Side-Effects Associated with Imatinib Mesylate (Gleevec ® ). https://app.cochat.ai/papers/10.1089/108076803322279426
- The paper
- Fraunfelder, F. W., Solomon, J., Druker, B. J., Esmaeli, B., & Kuyl, J. (2003). Ocular Side-Effects Associated with Imatinib Mesylate (Gleevec ® ). Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/108076803322279426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.